>>AMG102+Tarceva<<
I thought Amgen had already thrown in the towel. But you are right, ct.gov does show such an active IIS trial at u pittsburg.
>>I don't think it makes any difference whether ORR is primary, PFS is secondary, vice versa<<
If CMET drives tumor response rate, I would agree. However in the subgroup of EGFR mutation, clearly EGFR drives tumor growth. If de novo EGFR TKI resistance due to CMET/HGF is rare, then ficlatuzumab will not affect ORR, but will affect PFS if tumors do acquire resistance via CMET/HGF pathway.
You are probably right that the PFS difference is a data fluke due to chance imbalance and small sample size.
